Tashkent, Uzbekistan (UzDaily.com) -- GEROPHARM has received a registration certificate from the Ministry of Health of the Republic of Uzbekistan for biosimilars of insulin analogues glargine and lispro.

Thus, Uzbekistan became the third country in which GEROPHARM received a registration certificate for RinLease, and the fourth where RinGlar was registered.

Next year, it is planned to localize the production of insulin at the site of the Uzbek company Zuma Pharma. GEROPHARM will transfer to the partner the technology for the production of biosimilars of insulin analogues glargine, lispro and biphasic lispro in syringe pens and cartridges. An agreement on this was signed at SPIEF

GEROPHARM is a national manufacturer of biotech drugs that ensures drug safety in Russia. The company is engaged in the production of medicines on a full cycle, invests in technological development and the creation of a modern pharmaceutical infrastructure.